L-Arginine in diabetes: clinical and preclinical evidence.

Cardiovasc Diabetol

Department of Medicine, Division of Cardiology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Fleischer Institute for Diabetes Research (FIDAM), Einstein - Mount Sinai Diabetes Research Center (ES-DRC), Albert Einstein University College of Medicine, New York, NY, USA.

Published: April 2023

L-Arginine (L-Arg), is a semi-essential amino acid involved in the formation of nitric oxide. The functional relevance of L-Arg in diabetes mellitus has been evaluated both in animal models and in human subjects. In the literature there are several lines of evidence indicating that L-Arg has beneficial effects in diabetes and numerous studies advocate its administration to attenuate glucose intolerance in diabetic patients. Here we present a comprehensive overview of the main studies exploring the effects of L-Arg in diabetes, including preclinical and clinical reports on this topic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114382PMC
http://dx.doi.org/10.1186/s12933-023-01827-2DOI Listing

Publication Analysis

Top Keywords

l-arg diabetes
8
l-arginine diabetes
4
diabetes clinical
4
clinical preclinical
4
preclinical evidence
4
evidence l-arginine
4
l-arg
4
l-arginine l-arg
4
l-arg semi-essential
4
semi-essential amino
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!